Vivli, as part of the NIH Generalist Repository Ecosystem Initiative GREI, was delighted to be one of the repositories that researchers could use to request the data as part of the 2024 DataWorks! Prize. Of the GREI repositories, Vivli was the only one that focused on sharing the data from completed clinical trials.
About the Eligible Studies on Vivli
Vivli offered an array of 25 COVID-19 clinical trials that provided a unique and comprehensive exploration into the treatment and management of this disease.These landmark randomized controlled trials (RCTs) encompassed a wide spectrum of pharmacological agents, including Losartan, Hydroxychloroquine, Azithromycin, Colchicine, and Nitazoxanide, targeting various stages and severities of the disease state. The trials covered diverse COVID populations, ranging from those with severe acute respiratory syndrome to hospitalized and non-hospitalized patients, as well as high-risk groups.
By engaging with these trial data (including the protocol, CRFs, raw data, data dictionary) researchers contributed to the collective effort to combat the COVID-19 pandemic.
In total, there were 37 completed clinical trials on Vivli that were eligible studies for the DataWorks! Prize.To find out more about the overall challenge, please visit the main challenge website.